Search Results

You are looking at 41 - 50 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Clinical Treatment Decisions for Advanced Renal Cell Cancer

Toni K. Choueiri

carcinoma receiving vascular endothelial growth factor targeted therapy . J Urol 2011 ; 185 : 60 – 66 . 2. Manola J Royston P Elson P . Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the

Full access

Non–Clear Cell Renal Cancer: Features and Medical Management

Daniel Y. C. Heng and Toni K. Choueiri

References 1 Cohen HT McGovern FJ . Renal-cell carcinoma . N Engl J Med 2005 ; 353 : 2477 – 2490 . 2 Kovacs G Akhtar M Beckwith BJ . The Heidelberg classification of renal cell tumours . J Pathol 1997 ; 183 : 131 – 133

Full access

Kidney Cancer: Current and Novel Treatment Options

Eric Jonasch

“It has been an exciting 15 years for renal cell carcinoma,” noted Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Director of the Von Hippel–Lindau Clinical Center at The

Full access

Focal Takotsubo Cardiomyopathy With High-Dose Interleukin-2 Therapy for Malignant Melanoma

Senthil Damodaran, Ewa Mrozek, David Liebner, and Kari Kendra

: 3122 – 3131 . 10 White RL Jr Schwartzentruber DJ Guleria A . Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma . Cancer 1994 ; 74 : 3212

Full access

BPI20-021: Metastatic Renal Cell Carcinoma and Immunotherapy, Experience in a Third Level Hospital in Mexico City

Benigno Emmanuel Rodriguez Soto, Lorena López Zepeda, Daniela Vázquez Juarez, Alejandro Noguez Ramos, Alberto Villalobos Prieto, Samuel Rivera Rivera, Guillermo Manuel Olivares Beltrán, and Raquel Gerson Cwilich

Full access

Kidney Cancer, Version 3.2015

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

. Overview Renal cell carcinoma (RCC) constitutes approximately 3.9% of new cancers, with a median age of 64 years at diagnosis. The American Cancer Society estimated that 63,920 Americans would be diagnosed with and 13,860 would die of RCC in the United

Full access

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Christos Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley Somer, Jeffrey Sosman, Mary A. Dwyer, and Angela D. Motter

option for patients in both the favorable and poor/intermediate International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups. For the same update, the panel also discussed whether axitinib/pembrolizumab might be used in clinical

Full access

Principles of Immunotherapy

Anthony J. Olszanski

cancer,” he added. In the 21st century, the first cancer vaccine was approved worldwide in Russia for renal cell carcinoma in 2008. In fairly rapid succession, sipuleucel-T was approved for prostate cancer, the CTLA-4 inhibitor ipilimumab was approved

Full access

Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis

Somasundaram Subramaniam, Jason A. Zell, and Pamela L. Kunz

, everolimus inhibits expression of hypoxia-inducible factor and reduces vascular endothelial growth factor (VEGF) expression. Everolimus was initially approved by the FDA in 2009 for the second-line treatment of advanced renal cell carcinoma. Subsequently

Full access

Role of Immunotherapy for Renal Cell Cancer in 2011

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC